Clinical Trial

A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1)

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
An open-label, first-in-human, Phase 1 study in adult patients with relapsed advanced malignancies will be done to assess AUR107 safety, tolerability, pharmacokinetics, pharmacodynamics, and optimal biological dose.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-05-09; most recent amendment 2026-04-14.
Status change: Not Yet Recruiting → Recruiting 2024-01-29
Trial Details
NCT Number NCT05865002
Lead Sponsor Aurigene Discovery Technologies Limited
Conditions Relapsed Malignant Solid Neoplasm
Enrollment 50 participants
Start Date 2023-09-05
Primary Completion 2027-01 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-04-17